



Supporting Information

for *Adv. Sci.*, DOI: 10.1002/adv.202100808

Neuronal induction of bone-fat imbalance through osteocyte neuropeptide Y

*Yan Zhang, Chun-Yuan Chen, Yi-Wei Liu, Shan-Shan Rao, Yi-Juan Tan,
Yu-Xuan Qian, Kun Xia, Jie Huang, Xi-Xi Liu, Chun-Gu Hong, Hao Yin,
Jia Cao, Shi-Kai Feng, Ze-Hui He, You-You Li, Zhong-Wei Luo, Ben Wu,
Zi-Qi Yan, Tuan-Hui Chen, Meng-Lu Chen, Yi-Yi Wang, Zhen-Xing
Wang, Zheng-Zhao Liu, Ming-Jie Luo, Xiong-Ke Hu, Ling Jin, Teng-Fei
Wan, Tao Yue, Si-Yuan Tang, Hui Xie**

Supplemental information

Neuronal induction of bone-fat imbalance through osteocyte neuropeptide Y

*Yan Zhang[#], Chun-Yuan Chen[#], Yi-Wei Liu, Shan-Shan Rao, Yi-Juan Tan, Yu-Xuan Qian, Kun Xia,
Jie Huang, Xi-Xi Liu, Chun-Gu Hong, Hao Yin, Jia Cao, Shi-Kai Feng, Ze-Hui He, You-You Li,
Zhong-Wei Luo, Ben Wu, Zi-Qi Yan, Tuan-Hui Chen, Meng-Lu Chen, Yi-Yi Wang, Zhen-Xing
Wang, Zheng-Zhao Liu, Ming-Jie Luo, Xiong-Ke Hu, Ling Jin, Teng-Fei Wan, Tao Yue, Si-Yuan
Tang, Hui Xie^{*}*

[#] Yan Zhang and Chun-Yuan Chen contributed equally to this work.

^{*} Corresponding author: Hui Xie (huixie@csu.edu.cn).




Figure S1. Characterization of osteocytes and BMSCs. **A)** Osteocytes exhibited a stellate morphology with long dendritic processes under an optical microscope (**i**; Scale bar: 100 μm), expressed DMP1 protein (**ii**; Scale bar: 50 μm), but had no ability to produce ALP protein (**iii**; Scale bar: 100 μm). **B)** Flow cytometry analysis of expression of cell surface markers on BMSCs. The test samples were illustrated as blue curves and the isotype controls were illustrated as red curves. **C)** BMSCs could differentiate into osteoblasts and adipocytes, as detected by ARS (**i**) and ORO (**ii**) staining, respectively. Black arrows indicate the ARS-stained mineralized nodules and ORO-stained lipid droplets. Scale bar: 50 μm .




Figure S2. Protein expression of brain NPY. Western blotting for NPY protein in the brain tissues from normal male mice at different ages or female mice subjected to OVX or sham operation.




Figure S3. Identification of osteoblasts, monocytes/macrophages, and osteoclasts.

A) Immunofluorescence staining for OCN (**i**; Scale bar: 50 μm) and ALP staining (**ii**; Scale bar: 100 μm) in osteoblasts. **B)** Flow cytometry analysis of expression of F4/80 and CD11b in monocytes/macrophages. **C)** TRAP staining of osteoclasts formed by monocytes/macrophages treated with osteoclastic induction medium for 8 days. Scale bar: 100 μm .




Figure S4. Protein expression of Y1R in the femurs and primary BMSCs. **A)** Immunohistochemical staining for Y1R in the femur section from 4-month-old male wild-type mice. Secondary antibody only served as negative control. OCY: osteocyte; OB: osteoblast; TB: trabecular bone; BM: bone marrow. Scale bar: 50 μm . **B)** Immunofluorescence staining for Y1R in the cultured primary BMSCs. Scale bar: 50 μm .




Figure S6. Conditional targeting strategy for NPY and its expression in different tissues. **A)** Schematic diagram of the targeting strategy for generating mice harboring the conditional *Npy* allele in which exon 2 was flanked with two *loxP* sites. **B)** PCR genotyping of wild-type mice, *Npy*^{fl/fl} mice, *Npy*^{fl/fl} mice, *Dmp1-iCre* mice, and

Dmp1-iCre; Npy^{fl/fl} mice using primers for determining the insertion of loxP (up) and *iCre* (bottom). **C)** Western blotting for NPY expression in the bone marrow-depleted femurs, whole bone marrow cells, whole brain lysate, and hypothalamus from 4-month-old male *Npy^{fl/fl}* mice and *Dmp1-iCre; Npy^{fl/fl}* mice. **D)** Immunofluorescence staining for NPY in the brain tissues and **E)** quantification of mean intensity for the NPY-positive signals. Scale bar: 500 μm . $n = 3$ per group. Data are presented as mean \pm SD. Unpaired, two tailed student's *t*-test.




Figure S7. Detection of NPY and DMP1 expression in the brain tissues. Immunofluorescence double staining for DMP1 and NPY in the brain tissues from six 4-month-old male wild-type mice. Scale bar: 500 μm (up) or 20 μm (bottom).




Figure S8. Effects of osteocyte NPY deletion on bone mass, osteoclast formation and activity, body weight, daily intake of food and water, fat mass, lean mass, and metabolic indicators in mice. **A)** μ CT reconstruction images and **B)** quantification of bone microarchitecture parameters in femurs from 3-month-old male *Dmp1-iCre* mice, *Npy^{fl/fl}* mice, *Dmp1-iCre; Npy^{fl/fl}* mice, and their wild-type littermates. $n = 8-10$ per group. **C)** TRAP staining images and **D)** quantification of the number of osteoclasts (N. OCs) in distal femurs from male *Npy^{fl/fl}* mice and *Dmp1-iCre; Npy^{fl/fl}* mice at different ages. Scale bar: 50 μ m. $n = 5$ per group. **E)** ELISA test for serum CTX-I. $n = 5$ per group. **F)** TRAP staining images and **G)** quantification of the number of osteoclasts in distal femurs from female *Npy^{fl/fl}* mice and *Dmp1-iCre; Npy^{fl/fl}* mice subjected to OVX or sham operation. Scale bar: 50 μ m. $n = 5$ per group. **H)** ELISA test for serum CTX-I. $n = 5$ per group. **I)** TRAP staining showing the effect of NPY protein on osteoclast formation of RAW264.7 cells. **J)** Quantification of the number of TRAP⁺ osteoclasts (> 3 nuclei). Scale bar: 50 μ m. $n = 3$ per group. **K)** Body weight, **L)** lean mass, **M)** fat mass, and daily intake of food **N)** and water **O)** in age- and sex-matched *Npy^{fl/fl}* mice and *Dmp1-iCre; Npy^{fl/fl}* mice. $n = 10$ or 5 per group. The levels of **P)** serum total protein, **Q)** albumin, **R)** urea nitrogen, **S)** creatinine, **T)** blood glucose, **U)** total triglyceride, and **V)** total cholesterol in 3-month-old sex-matched *Npy^{fl/fl}* mice and *Dmp1-iCre; Npy^{fl/fl}* mice. $n = 5$ per group. Data are presented as mean \pm SD. For panel (B): one-way ANOVA with Bonferroni *post hoc* test. For panels (J), (N), and (O): unpaired, two tailed student's *t*-test. For other dot plots: two-way ANOVA with Bonferroni *post hoc* test. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure S9. Effects of NPY deletion in osteoblasts on bone mass. **A)** PCR genotyping of wild-type mice, *Npy*^{fl/-} mice, *Npy*^{fl/fl} mice, *Colla1-Cre/ERT2* mice, and *Colla1-Cre/ERT2*; *Npy*^{fl/fl} mice using primers for determining the insertion of loxP (up) and *Cre* (bottom). **B)** μ CT reconstruction images and **C)** quantification of bone microarchitecture parameters in femurs from 3-month-old male *Npy*^{fl/fl} mice and *Colla1-Cre/ERT2*; *Npy*^{fl/fl} mice treated with tamoxifen for consecutive 5 days and then left for two months. Scale bar: 1 mm. $n = 8$ per group. Data are presented as mean \pm SD. Unpaired, two tailed student's *t*-test. * $P < 0.05$.




Figure S10. Effects of NPY and OCY-CM on expression of a subset of pro-osteogenic/anti-adipogenic transcription factors. qRT-PCR analysis of mRNA levels of a subset of pro-osteogenic/anti-adipogenic transcription factors in BMSCs receiving different treatments under **A**) osteogenic or **B**) adipogenic induction for 3 days. $n = 3$ per group. Data are presented as mean \pm SD. Unpaired, two tailed student's t -test (differences between un-induced and control groups) or one-way ANOVA combined with Bonferroni *post hoc* test (differences among control, NPY, and OCY-CM groups). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Figure S11. Detection of the sympathetic and parasympathetic fibers in the bone tissues. Immunofluorescence double staining images for DMP1/TH and DMP1/VaChT in femurs from 4-month-old male wild-type mice. White arrows indicate the presence of the TH- or VaChT-positive neuronal fibers in the periosteum, cortical bone, trabecular bone, and bone marrow. CB: cortical bone. TB: trabecular bone; BM: bone marrow. Scale bar: 50 μ m.




Figure S12. SNS and PSNS activation or γ -Oryzanol administration induces no obvious effects on osteoclast formation and activity. **A)** Quantification of the number of TRAP⁺ osteoclasts in distal femurs from 3-month-old female *Npy*^{fl/fl} mice and *Dmp1-iCre; Npy*^{fl/fl} mice subjected to sham or OVX operation with solvent, Cle, or Riv treatments for two months. *n* = 5 per group. **B)** ELISA test for serum CTX-I. *n* = 5 per group. **C)** Quantification of the number of osteoclasts in distal femurs from 3-month-old female *Npy*^{fl/fl} mice and *Dmp1-iCre; Npy*^{fl/fl} mice subjected to sham or OVX operation with solvent or γ -Oryzanol treatments for two months. *n* = 5 per group. **D)** ELISA test for serum CTX-I. *n* = 5 per group. Data are presented as mean \pm SD. Two-way ANOVA combined with Bonferroni *post hoc* test. **P* < 0.05, ***P* < 0.01, ****P* < 0.001.

Table S1. Primer sequences for semiquantitative PCR and qRT-PCR.

Gene	Forward (5'-3')	Reverse (5'-3')
<i>Npy</i>	CGCCACGATGCTAGGTAACAA	TGTCGCAGAGCGGAGTAGTA
<i>Npy1R</i>	AAATGTGTCACTTGCGGCGTTC	AGTGTTGATTCGCTTGGTCTCACTG
<i>Npy2R</i>	ACCGCCATCGTTGCATTGT	TCAGGGAGTATTCCCGBAAGA
<i>Npy4R</i>	CCAACCACTCACAGTCACCTA	GAAACAAGAGACGAACCAGATGA
<i>Npy5R</i>	TTTGTACGAGACAATACTGC	TGCGCTTTTTTCATAACAGCCAT
<i>Npy6R</i>	GCAAGAGCAACAACCTCGGC	TGTCATGTGCATCCCTTTTACG
<i>Sp7</i>	ATGGCGTCCTCTCTGCTTG	TGAAAGGTCAGCGTATGGCTT
<i>Runx2</i>	GACTGTGGTTACCGTCATGGC	ACTTGGTTTTTCATAACAGCGGA
<i>Bglap</i>	CTGACCTCACAGATCCCAAGC	TGGTCTGATAGCTCGTCACAAG
<i>Alpl</i>	CCAACCTTTTTGTGCCAGAGA	GGCTACATTGGTGTGAGCTTTTT
<i>Postn</i>	TGGTATCAAGGTGCTATCTGCG	AATGCCAGCGTGCCATAA
<i>Pparγ</i>	TCGCTGATGCACTGCCTATG	GAGAGGTCCACAGAGCTGATT
<i>Fabp4</i>	AAGGTGAAGAGCATCATAACCCT	TCACGCCTTTCATAACACATTCC
<i>Cebpa</i>	CAAGAACAGCAACGAGTACCG	GTCACTGGTCAACTCCAGCAC
<i>Snai2</i>	CAGCGAACTGGACACACACA	ATAGGGCTGTATGCTCCCGAG
<i>Mef2a</i>	GGAGCTGGAAATAGTCCTGTGG	GGGAGACTTTGTAGGCATGACTT
<i>Tead1</i>	GAGCGACTCGGCAGATAAGC	CCACACGGCGGATAGATAGC
<i>Tead4</i>	TCCGCCAAATCTATGACAAGTTC	CGATGTTGGTATTGAGGTCTGC
<i>Smad3</i>	CACGCAGAACGTGAACACC	GGCAGTAGATAACGTGAGGGA
<i>Hif1α</i>	ACCTTCATCGGAACTCCAAAG	ACTGTTAGGCTCAGGTGAACT
<i>Elk4</i>	ATCTAACAATGGGGAGTTCAAGC	GGCTCGGCTGAGTTTATCATAAT
<i>Pitx1</i>	ATCGTCCGACGCTGATCTG	GCTTGTGAAGTGAGTGCGTT
<i>Junb</i>	TCACGACGACTCTTACGCAG	CCTTGAGACCCCGATAGGGA
<i>Taz</i>	ACCTGAAGTTGATGCGTTGGA	ATCCCTTTCTGGTAGACACCAT
<i>Adrb1</i>	TGGCTTACTGGCTTGTCTTG	TTTCCACTCGGGTCCTTG
<i>Adrb2</i>	GGACAACCTCATCCCTAA	AGAGTAGCCGTTCCATA
<i>Adrb3</i>	CAGTCCCTGCCTATGTTTG	TTCCTGGATTCTGCTCT
<i>Adra1</i>	CAAGGCCTCAAGTCCGGCCT	CTCTCGAGAAAACCTTGAGCAG
<i>Adra2</i>	GTGACACTGACGCTGGTTTG	CCAGTAACCCATAACCTCGTTG
<i>Chrna1</i>	TCTCAAGCAAAAAGTGGTC	ATTCCGAGATCTGCCTGTCT
<i>Chrna2</i>	CTCCCATCCTGCTTCCAG	GTTTGAACAGGCGGTCTC

<i>Chrna3</i>	CGCCTGTTCCAGTACCTGTT	CAGAGGGTTTCCATTTTCAGC
<i>Chrna4</i>	CTGTTCTATGATGGGCGTGTG	GATGAAGGCGTAGGTGATGTC
<i>Chrna5</i>	CCAGCTAATGACCACCAACG	GCTGCGTCCAAGTGACAGT
<i>Chrna6</i>	CCTGCACTCCGGTTTATGTC	CAGCCACAGATTGGTCTCCA
<i>Chrna7</i>	ACAATACTTCGCCAGCACCA	AAACCATGCACACCAATTCA
<i>Chrna9</i>	CAATGCTCTGCGTCCAGTAG	ACACCAGATCGCTGGGAATC
<i>Chrna10</i>	TCTGCTCCTGCTCTTTCTCC	CCACAGGTACAAGGTCAGCA
<i>Chrnβ1</i>	TGATGTGGTGCTGCTGAACAA	CAACGTCGAAATTTCCGTCAT
<i>Chrnβ2</i>	CGAAGTGAAGATGATGACCAGA	GTCCCAAAGACACAGACAAAGA
<i>Chrnβ3</i>	CGATGGAACGGAGAGTAAGG	AGAGGAAGATGCGGTCAAGA
<i>Chrnβ4</i>	GCAAGCCACTCTTCTACACCAT	GCACATTGAGGACACACACAGT
<i>Chrny</i>	GATGCAATGGTGCGACTATCGC	GCCTCCGGGTCAATGAAGATCC
<i>Chrnδ</i>	GAGAACGGTGAGTGGGAGATAGT	CTTGGAGATAAGCAGCAGGAAG
<i>Chrnξ</i>	AATGAAGAGCTTAGCCTGTA	TACACCTGCAAAAATCGTCCT
<i>Chrm1</i>	GCAGCAGCTCAGAGAGGTCACAG	GATGAAGGCCAGCAGGATGG
<i>Chrm2</i>	GCGGATCCTGTGGCCAACCAAGAC	CGAATTCACGATTTTGCGGGGCTA
<i>Chrm3</i>	AAGGCACGAAACGGTCATCT	GCAAACCTCTTAGCCAGCGT
<i>Chrm4</i>	AGCCGCAGCCGTGTTCAAA	TGGGTTGAGGGTTCGTGGCT
<i>Chrm5</i>	GTCTCCGTCATGACCATACTCTA	CCCGTTGTTGAGGTGCTTCTAC
<i>Gapdh</i>	AGGTCGGTGTGAACGGATTTG	TGTAGACCATGTAGTTGAGGTCA
<i>β-actin</i>	GGCTGTATTCCCCTCCATCG	CCAGTTGGTAACAATGCCATGT